Carl Icahn
Carl Icahn is a billionaire financier, ranking #18 on the 2007 Forbes 400 list with an estimated net worth of $14.5 billion.
Icahn built a name for himself in the 1980s as a corporate raider. After keeping quite for years, Icahn made a major comeback as a 'activist investor'. An activist investor agitates companies for changes, including buyouts, share buybacks, and dividend increases.
Icahn has successfully pushed for changes at Time Warner (NYSE: TWX) and Temple-Inland (NYSE: TIN), among others. Icahn won board seats at Motorola (NYSE: MOT) after first failing.
In 2007, Icahn's activism successfully pushed biotech company MedImmune into a sales agreement with AstraZeneca (NYSE: AZN). Icahn is also involved with biotech company Imclone Systems (Nasdaq: IMCL), where he is Chairman of the Board.
In early, 2008 Icahn activist target BEA Systems (Nasdaq: BEAS) was sold to Oracle (Nasdaq: ORCL). Icahn held a 13% stake in BEA.
Icahn is also involved with developments at Biogen Idec (Nasdaq: BIIB) and WCI Communities (NYSE: WCI), which both unsuccessfully explored sales. WCI rejected a $22 per share takeover offer from Icahn in early 2007, only to see its stock plummet on the housing slowdown.
In 2008, Icahn targeted Yahoo! (Nasdaq: YHOO) after the Internet company failed to work out an acceptable merger agreement with Microsoft (Nasdaq: MSFT) Microsoft walked away from its bid for Yahoo! after months of bickering.
http://xml.10kwizard.com/filing_raw.php?repo=tenk&ipage=5920596
http://xml.10kwizard.com/filing_raw.php?repo=tenk&ipage=5920586
NEW YORK--(BUSINESS WIRE)-- Imagine 360 Marketing has announced the unparalleled success of The 4th Annual New York Value Investing Congress, a Schwartz Tilson Information event. Despite the economic turmoil, on October 6-7, 2008 over 550 investors gathered at New York's Time Warner Center to meet and learn from some of the world's brightest investment minds. Even with the stock market unfolding downtown, the Congress was charged with energy and enthusiasm. After two days of intensive sessions filled with investing insight and stock picks, attendees walked away with ...
http://xml.10kwizard.com/filing_raw.php?repo=tenk&ipage=5917699
http://xml.10kwizard.com/filing_raw.php?repo=tenk&ipage=5915958
-
Form SC 13D/A IMCLONE SYSTEMS INC Filed by: ICAHN CARL C
-
More Comments from Carl Icahn from the Value Investing Congress
-
Icahn Says Boards Need To Be Held Accountable
-
Carl Icahn Speaking Now At Value Investing Congress--Doesn't Like Boards
-
Notable Mergers and Acquisitions of the Day 10/06: IMCL/LLY, VSH/IRF, EBAY
-
StreetInsider.com Reporting From Value Investing Congress Today
-
ImClone (IMCL) Enters Merger Agreement With Eli Lilly (LLY) For $70/Share
-
ImClone Announces Merger Agreement with Eli Lilly at $70 Per Share
-
Lilly to Acquire ImClone Systems in $6.5 Billion Transaction
-
Form SC 13D/A Guaranty Financial Group Filed by: ICAHN CARL C
-
Form 4 Guaranty Financial Group For: Oct 01 Filed by: ICAHN PARTNERS LP
-
Form 3 Guaranty Financial Group For: Oct 01 Filed by: ICAHN PARTNERS LP
-
ImClone's (IMCL) Carl Icahn Issues Statement On Takeover Bid
-
Form SC 13D/A XO HOLDINGS INC Filed by: ICAHN CARL C
-
ImClone Systems Issues Statement
-
Invitation to Ribbon-Cutting at Carl C. Icahn Charter Middle School on Oct. 7
-
Yahoo! (YHOO) Sees Interest On Rumor Microsoft Could Come Back To The Table
-
Yahoo!'s (YHOO) New Board Authorizes Fresh Talks With AOL
-
Icahn Responds to Cornelius
-
ImClone Systems (IMCL) Chairman Carl Icahn Sends Letter to Bristol-Myers
-
Bristol-Myers Squibb to Commence Cash Tender Offer for ImClone Systems at $62.00 per share
-
Icahn Expresses Deep Concerns About Exploding National Debt and Corporate Waste; Pushes for Corporate Governance Change
-
Icahn Launches Campaign to Improve Corporate Governance
-
The Conference Board Working Group on Hedge Fund Activism Issues Final Recommendations for Corporations and Investors
-
Form 8-K ICAHN ENTERPRISES L.P. For: Sep 17
-
Amylin Pharma (AMLN) Higher After Icahn Boosts Stake
-
Form SC 13D/A AMYLIN PHARMACEUTICALS Filed by: ICAHN CARL C
-
ImClone Systems Submits Letter to Bristol-Myers Squibb
-
Bristol-Myers Squibb Submits Letter to ImClone Board of Directors
-
Icahn Says $70/Share Isn't Adequate for ImClone (IMCL) -DJ
-
Unusual 11 Mid-Day Movers 9/10: ACBA, AVAV, STLD, RBN Higher; ENCO, DTG, GFIG, WM Lower
-
Analyst Expects Immediate $70/Share Offer for ImClone (IMCL) from Bristol-Myers Following News
-
Notable Mergers and Acquisitions of the Day 9/10: IMCL/BMY, VSH/IRF, MSFT/SRVY
-
ImClone (IMCL) Tells Bristol-Myers (BMY) $60/Sh Offer Is Inadequate; Says $70/Sh Offer On the Table From Another
-
ImClone Systems Issues Statement
-
Icahn Down $60M on Healthcare Stocks This Week (AMLN, BIIB, CYBX, REGN, FOLD)
-
Amylin Pharm (AMLN) Sinks On Byetta Pancreatitis Cases; Smart Money May Be Moving In
-
Form SC 13D/A XO HOLDINGS INC Filed by: ICAHN CARL C
-
Icahn's Icahn Capital Bumps Stake in Motorola (MOT), Shows New Small Stake in Emisphere (EMIS)
-
Carl Icahn's 13F Is Out
-
Form 13F-HR ICAHN CAPITAL LP For: Jun 30
-
Form 13F-HR ICAHN CARL C For: Jun 30
-
Frank J. Biondi, Jr. and John H. Chapple Appointed to Yahoo!'s Board of Directors
-
Form 8-K ICAHN ENTERPRISES L.P. For: Aug 11
-
Icahn Enterprises L.P. Reports Second Quarter Financial Results
-
Icahn Boosts Stake in Biogen Idec (BIIB) to 6% Following TYSABRI Sell-Off
-
Form SC 13D BIOGEN IDEC INC. Filed by: ICAHN CARL C
-
Form 10-Q ICAHN ENTERPRISES L.P. For: Jun 30
-
Enzon Pharma (ENZN) To Explore Options for Specialty Pharmaceuticals Business
-
Form 8-K/A ICAHN ENTERPRISES L.P. For: Jul 03
